Cargando…

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

Detalles Bibliográficos
Autores principales:	Hassett, Brian, Vicik, Steven, Fitzpatrick, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831761/ https://www.ncbi.nlm.nih.gov/pubmed/29651442 http://dx.doi.org/10.1155/2018/5047067

Ejemplares similares

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Etanercept (Enbrel(®)) alternative storage at ambient temperature
por: Shannon, Edel, et al.
Publicado: (2017)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”
por: Strowitzki, Thomas, et al.
Publicado: (2016)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products: Letter to the Editor
por: Hassett, Brian, et al.
Publicado: (2013)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Comment on “Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation”
por: Muratori, Paolo
Publicado: (2020)

Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits
por: Rekaya, Naceur, et al.
Publicado: (2020)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Response to: Comment on “Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation”
por: Shen, Yi, et al.
Publicado: (2021)

Etanercept in the Treatment of Generalized Annular Pustular Psoriasis
por: Lo Schiavo, Ada, et al.
Publicado: (2012)

Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

COVID-19 vaccine-associated autoimmune disorders: Comments
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Comment on: Alternate description of waveform: Pulsus bisferiens
por: Turner, Katja R, et al.
Publicado: (2015)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
por: Zhang, Lina, et al.
Publicado: (2021)

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe
por: Thakur, Kunal, et al.
Publicado: (2016)

Etanercept plus methotrexate: An effective combination therapy for recalcitrant pemphigus vulgaris
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2015)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Comment on “Olmsted Syndrome”
por: Gatault, Solene, et al.
Publicado: (2020)

Comment: “Subacute Combined Degeneration of the Spinal Cord Caused by Autoimmune Gastritis”
por: Fustes, Otto J. Hernandez, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25nhefrvtp6j9lk0taslja8guj